EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR–ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia

Johanna Pohl, Angela Litz, Omar El Ayoubi iD, Armando Rodríguez-Alfonso iD, Ludger Ständker iD, Mirja Harms iD, Jan Münch iD, Hassan Jumaa iD, Moumita Datta iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25158306 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Johanna Pohl und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology, Ulm University Medical Center, 89081 Ulm, Germany. Hauptthemen laut MEDLINE: Receptors, CXCR4, Fusion Proteins, bcr-abl. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, German Research Foundation (DFG), Bausteinprogramm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is characterized by reciprocal chromosomal translocation between chromosome 9 and 22, leading to the expression of constitutively active oncogenic BCR–ABL1 fusion protein. CXC chemokine receptor 4 (CXCR4) is essential for the survival of BCR–ABL1-transformed mouse pre-B cells, as the deletion of CXCR4 induces death in these cells. To investigate whether CXCR4 inhibition also effectively blocks BCR–ABL1-transformed cell growth in vitro, in this study, we explored an array of peptide-based inhibitors of CXCR4. The inhibitors were optimized derivatives of EPI-X4, an endogenous peptide antagonist of CXCR4. We observed that among all the candidates, EPI-X4 JM#170 (referred to as JM#170) effectively induced cell death in BCR–ABL1-transformed mouse B cells but had little effect on untransformed wild-type B cells. Importantly, AMD3100, a small molecule inhibitor of CXCR4, did not show this effect. Treatment with JM#170 induced transient JNK phosphorylation in BCR–ABL1-transformed cells, which in turn activated the intrinsic apoptotic pathway by inducing cJun, Bim, and Bax gene expressions. Combinatorial treatment of JM#170 with ABL1 kinase inhibitor Imatinib exerted a stronger killing effect on BCR–ABL1-transformed cells even at a lower dose of Imatinib. Surprisingly, JM#170 actively killed Sup-B15 cells, a BCR–ABL1+ human ALL cell line, but had no effect on the BCR–ABL1− 697 cell line. This suggests that the inhibitory effect of JM#170 is specific for BCR–ABL1+ ALL. Taken together, JM#170 emerges as a potent novel drug against Ph+ ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CXCR4Fusion Proteins, bcr-ablAnimalsMiceHumansPeptidesCell SurvivalApoptosisPrecursor Cell Lymphoblastic Leukemia-LymphomaCell Line, TumorPhiladelphia ChromosomePrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Stichwörter der Autor:innen

AMD3100BCR–ABL1CXCR4EPI-X4 derivativesImatinibcell survival

Substanzen

Receptors, CXCR4Fusion Proteins, bcr-ablPeptidesCXCR4 protein, human

Autor:innen und Institutionen

  • Institute of Immunology, Ulm University Medical Center, 89081 Ulm, Germany.
  • Core Facility Functional Peptidomics, Ulm University Medical Center, 89081 Ulm, Germany.
  • Core Unit Mass Spectrometry and Proteomics, Ulm University Medical Center, 89081 Ulm, Germany.
  • Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany.

ORCID-Profile: Omar El Ayoubi, Armando Rodríguez-Alfonso, Ludger Ständker, Mirja Harms, Jan Münch, Hassan Jumaa, Moumita Datta

Förderung

  • Deutsche Forschungsgemeinschaft
  • German Research Foundation (DFG)
  • Bausteinprogramm
  • Baden-Württemberg Foundation

Zitieren

APA

Pohl, J., Litz, A., El Ayoubi, O., Rodríguez-Alfonso, A., Ständker, L., Harms, M., Münch, J., Jumaa, H., & Datta, M. (2024). An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR–ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158306

Vancouver

Pohl J, Litz A, El Ayoubi O, Rodríguez-Alfonso A, Ständker L, Harms M, et al. An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR–ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158306

BibTeX
@article{Pohl2024,
  author = {Pohl, Johanna and Litz, Angela and El Ayoubi, Omar and Rodríguez-Alfonso, Armando and Ständker, Ludger and Harms, Mirja and Münch, Jan and Jumaa, Hassan and Datta, Moumita},
  title = {An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR–ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25158306}
}
Kostenlos starten →